# Carboplatin + Paclitaxel + Cetuximab (PCC) After Failure of Pembrolizumab +/- First-line Chemotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

> **NCT06725368** · PHASE2 · RECRUITING · sponsor: **Centre Paul Strauss** · enrollment: 46 (estimated)

## Conditions studied

- Head and Neck Cancer

## Interventions

- **DRUG:** PCC

## Key facts

- **NCT ID:** NCT06725368
- **Lead sponsor:** Centre Paul Strauss
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-24
- **Primary completion:** 2028-01
- **Final completion:** 2032-01
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2025-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06725368

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06725368, "Carboplatin + Paclitaxel + Cetuximab (PCC) After Failure of Pembrolizumab +/- First-line Chemotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06725368. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*